Demystifying Dolutegravir based antiretroviral drug regimens

ZIMBABWE recently joined other nations to adopt the new HIV treatment regimens that contain Dolutegravir (DTG).  The complete transition process for Zimbabwe however, will not take less than 10 months to be fully implemented considering that the country has over a million people on first line HIV medicines. By Michael Gwarisa and Dr. Simbarashe Mabaya Countries  adopt normative guidance by the World Health Organization (WHO) which is based on rigorous review and analysis of scientific evidence. Based on this review WHO develops recommendations which make up the next guidelines. Countries…

Share
Read More

Zim Commences DTG Drug Transition

DEPUTY Director HIV/AIDS and STIs in the ministry of health and child care (MoHCC), Dr Tsitsi Apollo says the country has already commenced its transition process from Tenovir/Lamuvidene/Efavirens to Dolutegravir (DTG), a first line regimen of Antiretroviral Therapy (ART) which has less side effected and a rapid viral suppression. By Michael Gwarisa The whole transition process will be completed come February 2020 and in the process, drugs such as Navirapine (NVP) will be phased out with indications on the ground confirming that healthcare providers have already been advised to limit…

Share
Read More